Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, CO 80204, USA.
Pain Manag. 2023 Sep;13(9):519-527. doi: 10.2217/pmt-2022-0068. Epub 2023 Oct 18.
Xtampza ER (Collegium Pharmaceutical, MA, USA) is an abuse-deterrent formulation (ADF) of oxycodone intended to deter tampering for use by unintended routes of administration. We assessed whether Xtampza ER exposures were less likely to result in severe medical outcomes relative to other opioid analgesic exposures. Exposures reported to participating poison centers between 2016 and 2021 inclusive that were followed to a known medical outcome were analyzed. Xtampza ER was compared with other ADF opioids, non-ADF extended-release opioids, single-entity oxycodone immediate-release, unspecified oxycodone and unspecified morphine. No Xtampza ER exposures involved unintended routes of administration. Xtampza ER exposures were less likely to be abuse, misuse or suspected suicidal, and medical outcomes were less severe than comparators.
Xtampza ER（美国 Collegium Pharmaceutical 公司）是一种阿片类药物盐酸羟考酮的控释制剂（ADF），旨在防止篡改以通过非预期途径给药。我们评估了 Xtampza ER 暴露相对于其他阿片类镇痛药暴露是否不太可能导致严重的医疗后果。对 2016 年至 2021 年期间报告给参与毒理中心并随访至已知医疗结果的暴露进行了分析。将 Xtampza ER 与其他 ADF 阿片类药物、非 ADF 延长释放阿片类药物、单一实体盐酸羟考酮即时释放、未指定盐酸羟考酮和未指定吗啡进行了比较。没有 Xtampza ER 暴露涉及非预期途径给药。Xtampza ER 暴露滥用、误用或疑似自杀的可能性较小，医疗结果也比对照组更轻微。
